

Nalini R Shastri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4907528/publications.pdf>

Version: 2024-02-01

64
papers

1,718
citations

279487

23
h-index

301761

39
g-index

65
all docs

65
docs citations

65
times ranked

2227
citing authors

#	ARTICLE	IF	CITATIONS
1	Multidrug co-crystals: towards the development of effective therapeutic hybrids. <i>Drug Discovery Today</i> , 2016, 21, 481-490.	3.2	164
2	Co amorphous systems: A product development perspective. <i>International Journal of Pharmaceutics</i> , 2016, 515, 403-415.	2.6	139
3	Emu oil based nano-emulgel for topical delivery of curcumin. <i>International Journal of Pharmaceutics</i> , 2016, 506, 222-236.	2.6	80
4	Micellar carriers for the delivery of multiple therapeutic agents. <i>Colloids and Surfaces B: Biointerfaces</i> , 2015, 135, 291-308.	2.5	78
5	Cellulose based polymers in development of amorphous solid dispersions. <i>Asian Journal of Pharmaceutical Sciences</i> , 2019, 14, 248-264.	4.3	76
6	Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. <i>Acta Pharmaceutica Sinica B</i> , 2012, 2, 502-508.	5.7	64
7	Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: A case study with aceclofenac. <i>International Journal of Pharmaceutics</i> , 2014, 461, 459-468.	2.6	63
8	Evaluation of the inhibitory potential of HPMC, PVP and HPC polymers on nucleation and crystal growth. <i>RSC Advances</i> , 2016, 6, 77569-77576.	1.7	63
9	Solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of glimepiride: development and antidiabetic activity in albino rabbits. <i>Drug Delivery</i> , 2015, 22, 499-508.	2.5	58
10	Formulation and evaluation of cyclodextrin complexes for improved anticancer activity of repurposed drug: Niclosamide. <i>Carbohydrate Polymers</i> , 2019, 212, 252-259.	5.1	55
11	Development of Taste Masked Fast Disintegrating Films of Levocetirizine Dihydrochloride for Oral Use. <i>Current Drug Delivery</i> , 2010, 7, 21-27.	0.8	47
12	Fast dissolving drug-drug eutectics with improved compressibility and synergistic effects. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 104, 82-89.	1.9	39
13	Continuous manufacturing of co-crystals: challenges and prospects. <i>Drug Delivery and Translational Research</i> , 2018, 8, 1726-1739.	3.0	39
14	Enhanced solubility, permeability, and tabletability of nicorandil by salt and cocrystal formation. <i>CrystEngComm</i> , 2021, 23, 227-237.	1.3	37
15	Hepatoprotective Cocrystals and Salts of Riluzole: Prediction, Synthesis, Solid State Characterization, and Evaluation. <i>Crystal Growth and Design</i> , 2018, 18, 1047-1061.	1.4	36
16	Preparation, characterization, and cytotoxicity studies of niclosamide loaded mesoporous drug delivery systems. <i>International Journal of Pharmaceutics</i> , 2017, 528, 202-214.	2.6	34
17	Syringic Acid: Structural Elucidation and Co-Crystallization. <i>Crystal Growth and Design</i> , 2016, 16, 4679-4687.	1.4	32
18	Spherical Agglomeration of Platy Crystals: Curious Case of Etodolac. <i>Crystal Growth and Design</i> , 2016, 16, 4034-4042.	1.4	30

#	ARTICLE	IF	CITATIONS
19	Crystal engineered albendazole with improved dissolution and material attributes. CrystEngComm, 2016, 18, 1489-1494.	1.3	30
20	Ionic, Neutral, and Hybrid Acid-Base Crystalline Adducts of Lamotrigine with Improved Pharmaceutical Performance. Crystal Growth and Design, 2015, 15, 5816-5826.	1.4	29
21	Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and <i>in vivo</i> evaluation. Drug Development and Industrial Pharmacy, 2017, 43, 611-617.	0.9	28
22	Co amorphous valsartan nifedipine system: Preparation, characterization, <i>in vitro</i> and <i>in vivo</i> evaluation. European Journal of Pharmaceutical Sciences, 2019, 139, 105048.	1.9	26
23	Near infra red spectroscopy: a tool for solid state characterization. Drug Discovery Today, 2017, 22, 1835-1843.	3.2	25
24	Improved anti-diabetic activity of glibenclamide using oral self nano emulsifying powder. Journal of Microencapsulation, 2015, 32, 54-60.	1.2	23
25	Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, <i>in vitro</i> , <i>in vivo</i> evaluation, and scale up feasibility study. Drug Delivery and Translational Research, 2020, 10, 903-918.	3.0	23
26	An <i>ab initio</i> molecular dynamics method for cocrystal prediction: validation of the approach. CrystEngComm, 2019, 21, 7233-7248.	1.3	23
27	Generation and Evaluation of Pharmacologically Relevant Drug-Drug Cocrystal for Gout Therapy. Crystal Growth and Design, 2020, 20, 3577-3583.	1.4	22
28	Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilstazol. International Journal of Pharmaceutics, 2015, 491, 26-34.	2.6	21
29	Role of Valsartan as an Antiplasticizer in Development of Therapeutically Viable Drug-Drug Coamorphous System. Crystal Growth and Design, 2018, 18, 1944-1950.	1.4	20
30	Hepatoprotective Cocrystals of Isoniazid: Synthesis, Solid State Characterization, and Hepatotoxicity Studies. Crystal Growth and Design, 2019, 19, 5161-5172.	1.4	20
31	Quantification of niclosamide polymorphic forms - A comparative study by Raman, NIR and MIR using chemometric techniques. Talanta, 2019, 199, 679-688.	2.9	19
32	Preparation and optimization of nano-sized cocrystals using a quality by design approach. CrystEngComm, 2020, 22, 2304-2314.	1.3	19
33	Mechanochemical synthesis of brexpiprazole cocrystals to improve its pharmaceutical attributes. CrystEngComm, 2019, 21, 800-806.	1.3	18
34	Effect of HPMC concentration on crystal habit of nifedipine. CrystEngComm, 2015, 17, 1615-1624.	1.3	17
35	Effect of surfactant concentration on nifedipine crystal habit and its related pharmaceutical properties. Journal of Crystal Growth, 2015, 422, 44-51.	0.7	17
36	A Validated Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Tenofovir, Emtricitabine, and Efavirenz and Statistical Approach to Determine the Effect of Variables. ISRN Chromatography, 2013, 2013, 1-8.	0.6	16

#	ARTICLE	IF	CITATIONS
37	Determination of precipitation inhibitory potential of polymers from amorphous solid dispersions. Drug Development and Industrial Pharmacy, 2018, 44, 1933-1941.	0.9	16
38	Brexiprazoleâ€“catechol cocrystal: structure elucidation, excipient compatibility and stability. CrystEngComm, 2019, 21, 6703-6708.	1.3	14
39	Designed Isomorphism of Nifedipine: A Joint Experimental and Molecular Simulation Study with Screened Solvents and Antisolvents. Crystal Growth and Design, 2014, 14, 326-338.	1.4	13
40	Design and optimization of disintegrating pellets of MCC by non-aqueous extrusion process using statistical tools. European Journal of Pharmaceutical Sciences, 2016, 84, 146-156.	1.9	12
41	Tuning Diffusion Permeability of an Anti-Retroviral Drug, Emtricitabine, via Multicomponent Crystallizations. Crystal Growth and Design, 2021, 21, 1548-1561.	1.4	12
42	Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation. Archives of Pharmacal Research, 2015, 38, 801-812.	2.7	11
43	Impact of Nisoldipine Crystal Morphology on Its Biopharmaceutical Properties: A Layer Docking Assisted Study. Organic Process Research and Development, 2015, 19, 1912-1917.	1.3	10
44	Generation of Hollow Crystals of a Drug with Lamellar Structure Forming Ability. Crystal Growth and Design, 2017, 17, 1480-1483.	1.4	10
45	Classification of the crystallization tendency of active pharmaceutical ingredients (APIs) and nutraceuticals based on their nucleation and crystal growth behaviour in solution state. Drug Delivery and Translational Research, 2020, 10, 70-82.	3.0	10
46	Design of a novel type IV lipid-based delivery system for improved delivery of drugs with low partition coefficient. Journal of Liposome Research, 2015, 25, 325-333.	1.5	9
47	Development and validation of RP-HPLC method for glimepiride and its application for a novel self-nanoemulsifying powder (SNEP) formulation analysis and dissolution study. Journal of Analytical Science and Technology, 2014, 5, .	1.0	7
48	The role of surface chemistry in crystal morphology and its associated properties. CrystEngComm, 2015, 17, 6646-6650.	1.3	7
49	Rufinamide: Crystal structure elucidation and solid state characterization. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149, 185-192.	1.4	7
50	Modulating drug release profiles by lipid semi solid matrix formulations for BCS class II drug â€“ an<i>in vitro</i>and an<i>in vivo</i>study. Drug Delivery, 2015, 22, 418-426.	2.5	6
51	Hollow crystal generation through polymorphic transformation â€“ a case study of flufenamic acid. CrystEngComm, 2018, 20, 275-279.	1.3	6
52	Polymorphic transformation as a result of atovaquone incompatibility with selected excipients. Journal of Thermal Analysis and Calorimetry, 2018, 131, 2129-2139.	2.0	6
53	RP-HPLC SEPARATION METHOD FOR INDIVIDUAL COMPONENTS OF POLYCAP IN PRESENCE OF THEIR DEGRADATION/INTERACTION PRODUCTS. Journal of Liquid Chromatography and Related Technologies, 2012, 35, 662-676.	0.5	5
54	Can vacuum morphologies predict solubility and intrinsic dissolution rate? A case study with felodipine polymorph form IV. Journal of Computational Science, 2015, 10, 178-185.	1.5	5

#	ARTICLE	IF	CITATIONS
55	Polymerâ€™Drug Conjugate in Focal Drug Delivery. Advances in Delivery Science and Technology, 2014, , 117-147.	0.4	4
56	Exploration of crystal simulation potential by fluconazole isomorphism and its application in improvement of pharmaceutical properties. Journal of Crystal Growth, 2014, 406, 18-25.	0.7	4
57	The effects of <i>cis</i> and <i>trans</i> butenedioic acid on the physicochemical behavior of lumefantrine. CrystEngComm, 2021, 24, 156-168.	1.3	4
58	Lipid Carriers: Role and Applications in Nano Drug Delivery. , 2017, , 253-289.		3
59	HPLC AND LC-MS STUDIES ON STRESS DEGRADATION BEHAVIOR OF LEVOCETIRIZINE AND DEVELOPMENT OF A VALIDATED SPECIFIC STABILITY-INDICATING METHOD. Journal of Liquid Chromatography and Related Technologies, 2011, 34, 955-965.	0.5	2
60	Nanocrystals for Delivery of Therapeutic Agents. , 2017, , 291-316.		2
61	Overview of Multicomponent Solid Forms. Journal of Nanotoxicology and Nanomedicine, 2018, 3, 23-48.	0.7	2
62	Multicomponent Solid Forms. Advances in Medical Technologies and Clinical Practice Book Series, 2018, , 273-300.	0.3	1
63	Inorganic Nanocompositesâ€™A New Paradigm in Drug Delivery. , 2017, , 317-357.		0
64	Overview of Multicomponent Solid Forms. , 2020, , 65-102.		0